Throughout the last three months, 13 analysts have evaluated Hims & Hers Health HIMS, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) issued a warning about topical finasteride, a hair-loss treatment sold ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide ...

But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per share. Its momentum hasn’t stopped as it’s also gained 25.8% ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside 30-day short-term view” on the shares. Citi expects ...

Investing.com -- Shares of Hims Hers Health Inc (NYSE:HIMS) closed down 1.9% following the FDA’s issuance of a warning letter regarding compounded topical finasteride products, which are ...

Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per ...